Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events
Bimekizumab demonstrated significant effectiveness and an acceptable safety profile in a real-world setting. Baseline PASI, nail involvement, and prior biologic failures influenced early treatment response. Identifying predictors of ESR and adverse events can guide personalized therapeutic approaches, optimizing outcomes for psoriasis patients.
Authors
- Enzo Errichetti (ORCID: https://orcid.org/0000-0002-7152-6136)
- Zeno Fratton (ORCID: https://orcid.org/0000-0002-7454-1999)
- Vincenzo Maione (ORCID: https://orcid.org/0000-0002-0420-5009)
- Stefano Bighetti (ORCID: https://orcid.org/0009-0006-2781-6909)
- Mariachiara Arisi (ORCID: https://orcid.org/0000-0001-6307-6174)
- Giuseppe Stinco (ORCID: https://orcid.org/0000-0002-2392-9504)
- Luca Bettolini (ORCID: https://orcid.org/0000-0003-4374-802X)
- Cinzia Buligan (ORCID: https://orcid.org/0000-0002-4480-2027)
Institutions
- University of Udine (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Brescia (IT)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ptt.s514249
- Citations
- 10
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 7.97